BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 35703391)

  • 1. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.
    Rogers TR; Verweij PE; Castanheira M; Dannaoui E; White PL; Arendrup MC;
    J Antimicrob Chemother; 2022 Jul; 77(8):2053-2073. PubMed ID: 35703391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
    Pfaller MA
    Am J Med; 2012 Jan; 125(1 Suppl):S3-13. PubMed ID: 22196207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.
    Gamaletsou MN; Walsh TJ; Sipsas NV
    Turk J Haematol; 2018 Mar; 35(1):1-11. PubMed ID: 29391334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of antifungal susceptibility: Review of literature.
    Hadrich I; Ayadi A
    J Mycol Med; 2018 Sep; 28(3):574-584. PubMed ID: 29773435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of antifungal resistance and its impact on clinical practice.
    Alcazar-Fuoli L; Mellado E
    Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of fungal susceptibility testing.
    Posteraro B; Sanguinetti M
    Future Microbiol; 2014; 9(8):947-67. PubMed ID: 25302953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.
    Albataineh MT; Sutton DA; Fothergill AW; Wiederhold NP
    Infect Dis Clin North Am; 2016 Mar; 30(1):13-35. PubMed ID: 26739605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
    Hoenigl M; Arastehfar A; Arendrup MC; Brüggemann R; Carvalho A; Chiller T; Chen S; Egger M; Feys S; Gangneux J-P; Gold JAW; Groll AH; Heylen J; Jenks JD; Krause R; Lagrou K; Lamoth F; Prattes J; Sedik S; Wauters J; Wiederhold NP; Thompson GR
    Clin Microbiol Rev; 2024 Jun; 37(2):e0007423. PubMed ID: 38602408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal drug resistance: does it matter?
    Rogers TR
    Int J Infect Dis; 2002 Mar; 6 Suppl 1():S47-53. PubMed ID: 12044289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibility testing. New technology and clinical applications.
    Pfaller MA; Yu WL
    Infect Dis Clin North Am; 2001 Dec; 15(4):1227-61. PubMed ID: 11780273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial strategies for combating invasive fungal infections.
    Spitzer M; Robbins N; Wright GD
    Virulence; 2017 Feb; 8(2):169-185. PubMed ID: 27268286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Issues in Antifungal Resistance.
    Perfect JR; Ghannoum M
    Infect Dis Clin North Am; 2020 Dec; 34(4):921-943. PubMed ID: 33131575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses.
    Jacobs SE; Wengenack NL; Walsh TJ
    Semin Respir Crit Care Med; 2020 Feb; 41(1):115-130. PubMed ID: 32000288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal resistance in superficial mycoses.
    Gupta AK; Venkataraman M
    J Dermatolog Treat; 2022 Jun; 33(4):1888-1895. PubMed ID: 34132155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?
    Bassetti M; Vena A; Bouza E; Peghin M; Muñoz P; Righi E; Pea F; Lackner M; Lass-Flörl C
    Clin Microbiol Infect; 2020 Aug; 26(8):1024-1033. PubMed ID: 32120042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mycoses].
    Yamazumi T; Furuta I
    Rinsho Byori; 2002 Sep; 50(9):853-9. PubMed ID: 12386962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal Susceptibility Testing and Identification.
    Kidd SE; Crawford LC; Halliday CL
    Infect Dis Clin North Am; 2021 Jun; 35(2):313-339. PubMed ID: 34016280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.